Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793524 | 1.00 | MEP1B (0.50) | MEP1BDAOMRGPRX4MPOPNMT | |
| Hydrochloric Acid SCHEMBL25370222 | 0.98 | MEP1B (0.49) | MEP1BDAOMRGPRX4MPOPNMT | |
| Hydrochloric Acid SCHEMBL30580212 | 0.98 | MEP1B (0.49) | MEP1BDAOMRGPRX4MPOPNMT | |
| SCHEMBL4242523 | 0.85 | TAAR1 (0.61) | MEP1BDAOMRGPRX4MPOMAOB | |
| Hydrochloric Acid SCHEMBL2211546 | 0.84 | TAAR1 (0.59) | MEP1BDAOMAOBDRD1HCRTR1 | |
| SCHEMBL12696913 | 0.81 | MAOB (0.41) | PNMTENPP2MAOBLOXL2TAAR1 | |
| SCHEMBL756850 | 0.81 | DHFR (0.51) | PNMTENPP2MAOBLOXL2HCRTR1 | |
| SCHEMBL1776057 | 0.81 | MEP1B (0.54) | MEP1BDAOMRGPRX4MPOENPP2 | |
| SCHEMBL1776056 | 0.81 | MEP1B (0.54) | MEP1BDAOMRGPRX4MPODRD1 | |
| SCHEMBL10913301 | 0.81 | MEP1B (0.50) | MEP1BDAOMRGPRX4MPODRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-28 | — | — | US | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245588-A1 | Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | disclosed |
| EP-1542996-A2 | OCTAHYDRO-2-H-NAPHTHO 1,2-F INDOLE-4-CARBOXAMIDE DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1318811-A4 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004026248-A2 | OCTAHYDRO-2-H-NAPHTHO[1,2-F] INDOLE-4-CARBOXAMIDE DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-1318811-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6545023-B2 | For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| WO-2002013824-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR1, CCRL2, CCR5 | MEP1B 1016/4885DAO 3731/4885MRGPRX4 46/4885 |
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | KCNA4, KCNMB4, KCNA7 | MEP1B 530/4885DAO 4258/4885MRGPRX4 257/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | MEP1B 3296/4885DAO 3793/4885MRGPRX4 3022/4885 |
| US-20050245588-A1 | Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | MEP1B 4352/4885DAO 3647/4885MRGPRX4 126/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEP1B 3296/4885DAO 3793/4885MRGPRX4 3022/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | MEP1B 2968/4885DAO 4556/4885MRGPRX4 4106/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | MEP1B 3924/4885DAO 4313/4885MRGPRX4 4623/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEP1B 3296/4885DAO 3793/4885MRGPRX4 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.